Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar...
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a...
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.33 | 5.02076255191 | 26.49 | 29.07 | 25.18 | 66418 | 27.14031865 | CS |
4 | 2.98 | 11.9967793881 | 24.84 | 29.07 | 22.51 | 70056 | 25.16712898 | CS |
12 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
26 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
52 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
156 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
260 | 2.32 | 9.09803921569 | 25.5 | 31.13 | 22.51 | 59839 | 25.31425505 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約